Since the start of the year, Ocugen (NASDAQ: OCGN) has been on fire. The biotech's shares have gained an eye-popping 122%, far surpassing the performance of small-cap growth stocks this year. (See the following graph.) What's fueling this rally? Is Ocugen's stock still a strong buy? Let's dig deeper ...
motleyfoolusx:ocgn
Image source: The Motley Fool. Ocugen (NASDAQ: OCGN) Q4 2023 Earnings Call Apr 02, 2024, 8:30 a.m. ET Operator Continue reading
motleyfoolusx:ocgn
